Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LENTI-COL-01
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
LENTI-COL-01 is an investigational, preclinical-stage therapeutic cancer vaccine being developed by Theravectys for the treatment of colorectal cancer. The vaccine is built on Theravectys's proprietary lentiviral vector platform, which utilizes non-integrative lentiviral vectors designed to directly target and transduce dendritic cells in vivo. This transduction enables the presentation of tumor-associated antigens to the immune system, triggering a potent, long-lasting cellular immune response (specifically cytotoxic T-cell immunity) alongside antibody production to eliminate colorectal cancer cells.
02
Targets
MHC I (MHC class I})γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on LENTI-COL-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LENTI-COL-01.